Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

This single arm study reported that at 14 month median follow-up, 65% of 91 patients had an overall response suggesting that venetoclax has clinical activity in patients with relapsed or refractory disease. Final analysis is expected in 2019.

The author of a related commentary notes that the results of this trial are reassuring and have clinical implications, especially since ibrutinib has been approved as a first-line treatment for patients with chronic lymphocytic leukaemia.

 

Venetoclax is also recommended by NICE for use within the Cancer Drugs Fund, within its marketing authorisation, as an option for treating chronic lymphocytic leukaemia.